Global expansion Recent regulatory approvals and product launches in multiple regions (Canada 2026 approval for Hermia platform; US/Canada upgrades already rolled out) indicate momentum and a growing international footprint. Leverage these expansions to target regional nuclear medicine centers, academic hospitals, and private imaging groups seeking standardized multimodality software and dosimetry across sites.

Integrated dosimetry Hermia now offers advanced voxel dosimetry and single time point dosimetry capabilities, addressing tools for personalized treatment planning. Sales plays should target departments building theranostics programs, mRNA or radiopharmaceutical workflows, and centers aiming to streamline dosimetry to improve patient throughput and treatment accuracy.

Multimodality leadership Leadership in multimodality PET/CT/MR and SPECT/CT viewing software with ongoing upgrades positions Hermes as a comprehensive imaging workflow solution. Target large hospitals and imaging networks prioritizing vendor-agnostic solutions that consolidate software across scanners from different vendors to reduce training and interoperability friction.

Strategic partnerships Recent collaborations to integrate Hermia with VERITON-CT and ongoing software enhancements show a channel-friendly approach. Explore co-marketing and technology-partner opportunities with scanner manufacturers, imaging centers, and integrated care providers to accelerate adoption and create bundled offerings.

SME affordability Company revenue in the low-to-mid tens of millions with a mid-sized employee base suggests agility and close customer support. Position Hermia as a cost-effective, scalable solution for mid-market hospitals and regional centers seeking robust software with strong service commitments and rapid ROI through improved workflow efficiency.